

Rashes in Infants and Children

Gary Bonfante
Amy Dunn

REFERENCES

1. Sawyer MH: Enterovirus infections: diagnosis and treatment. *Curr Opin Pediatr* 13: 65, 2001.
2. Zaoutis T, Klein JD: Enterovirus infections. *Pediatr Rev* 19: 183, 1998.
3. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402790.htm> (U.S. Food and Drug Administration: Lidocaine viscous: drug safety communication - boxed warning required - should not be used to treat teething pain. Posted June 24, 2014.) Accessed July 3, 2014.
4. Centers for Disease Control and Prevention: Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 62 (RR04): 1, 2013.
5. Waggoner-Fountain LA, Grossman LB: Herpes simplex virus. *Pediatr Rev* 25: 86, 2004.
6. Seward J, Watson B, Peterson C, et al: Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. *JAMA* 287: 606, 2002.
7. Weinmann S, Chun C, Schmid DS, et al: Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. *J Infect Dis* 208: 1859, 2013.
8. Heininger U, Seward JF: Varicella. *Lancet* 368: 1365, 2006.
9. Klassen TP, Hartling L: Acyclovir for treating varicella in otherwise healthy children and adolescents. *Cochrane Database Syst Rev* 4: CD002980, 2005.
10. Macartney K, Heywood A, McIntyre P: Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. *Cochrane Database Syst Rev* 6: CD001833, 2014.
11. Shy R: Tinea corporis and tinea capitis. *Pediatr Rev* 28: 167, 2007.
12. Kakourou T, Uksal U, European Society for Pediatric Dermatology: Guidelines for the management of tinea capitis in children. *Pediatr Dermatol* 27: 226, 2010.
13. Gupta AK, Drummond-Main C: Meta-analysis of randomized, controlled trials comparing particular doses of griseofulvin and terbinafine for the treatment of tinea capitis. *Pediatr Dermatol* 30: 1, 2013.
14. Stanley JR, Amagai M: Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. *N Engl J Med* 355: 1800, 2006.
15. Kaplan SL, Behnoosh A, Pio L, et al: Linezolid for the treatment of methicillin-resistant *Staphylococcus aureus* infections in children. *Pediatr Infect Dis J* 22: S178, 2003.
16. Wajima T, Chiba N, Morozumi M, et al: Prevalence of macrolide resistance among group A streptococci isolated from pharyngotonsillitis. *Microb Drug Resist* 20: 431, 2014.
17. Jackson MA, Newland JG: Staphylococcal infections in the era of MRSA. *Pediatr Rev* 32: 522, 2011.
18. Wathen D, Halloran DR: Blood culture associations in children with a diagnosis of cellulitis in the era of methicillin-resistant *Staphylococcus aureus*. *Hosp Pediatr* 3: 103, 2013.
19. Chira S, Miller LG: *Staphylococcus aureus* is the most common identified cause of cellulitis: a systematic review. *Epidemiol Infect* 138: 313, 2010.
20. Centers for Disease Control and Prevention: Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 62 (RR02): 1, 2013.
21. Pickering LK, Baker CJ, Kimberlin DW, Long SS (eds): Meningococcal infections, in: *Red Book: 2009 Report of the Committee on Infectious Diseases*, 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009: 455.
22. Meinking TL, Villar ME, Vicaria M, et al: The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). *Pediatr Dermatol* 27: 19, 2010.
23. Nigen S, Knowles SR, Shear NH: Drug eruptions: approaching the diagnosis of drug-induced skin diseases. *J Drugs Dermatol* 2: 278, 2003.
24. Shah B, Lucchesi M: Drug induced hypersensitivity syndrome, in: *Atlas of Pediatric Emergency Medicine*. New York, NY: McGraw-Hill, 2006: 285.
25. Lamoreux MR, Sternbach MR, Hsu WT: Erythema multiforme. *Am Fam Physician* 74: 1883, 2006.
26. Son MBF, Newburger JW: Kawasaki disease. *Pediatr Rev* 34: 151, 2013.
27. Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL: Kawasaki disease: an overview. *Curr Opin Infect Dis* 21: 263, 2008.
28. Manlhiot C, Yeung RSM, Clarizia NA, Chahal N, McCrindle BW: Kawasaki disease at the extremes of the age spectrum. *Pediatrics* 124: e410, 2009.
29. Newburger JW, Takahashi M, Gerber MA, et al: Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Circulation* 110(17): 2747–2771, 2004.
30. Saulsbury F: Clinical update: Henoch-Schönlein purpura. *Lancet* 369: 976, 2007.
31. Piram M, Mahr A: Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. *Curr Opin Rheumatol* 25: 171, 2013.
32. Roberts PF, Waller TA, Brinker TM, et al: Henoch-Schönlein purpura: a review article. *South Med J* 100: 821, 2007.